Literature DB >> 34245816

Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report.

Prince Singh1, Candace F Granberg2, Peter C Harris3, John C Lieske4, Jeffrey H Licht5, Andrew Weiss6, Dawn S Milliner7.   

Abstract

Primary hyperoxaluria (PH) is a group of genetic disorders that result in an increased hepatic production of oxalate. PH type 3 (PH3) is the most recently identified subtype and results from mutations in the mitochondrial 4-hydroxy-2-oxoglutarate aldolase gene (HOGA1). To date, there have been 2 cases of kidney failure reported in PH3 patients. We present a case of a young man with a history of recurrent urinary tract infections and voiding dysfunction who developed kidney failure at 33 years of age. He developed a bladder stone and bilateral staghorn calculi at 12 years of age. Initial metabolic evaluation revealed hyperoxaluria with very low urinary citrate excretion on multiple measurements for which he was placed on oral citrate supplements. Further investigation of the hyperoxaluria was not completed as the patient was lost to follow-up observation until he presented at 29 years of age with chronic kidney disease stage 4 (estimated glomerular filtration rate 24mL/min/1.73m2). Hemodialysis 3 times a week was started at 33 years of age, and subsequent genetic testing revealed a homozygous HOGA1 mutation (C.973G>A p.Gly325Ser) diagnostic of PH3. The patient is currently being evaluated for all treatment options including possible liver/kidney transplantation. All cases of a childhood history of recurrent urinary stone disease with marked hyperoxaluria should prompt genetic testing for the 3 known PH types. Hyperhydration and crystallization inhibitors (citrate) are standard of care, but the role of RNA interference agents for all 3 forms of PH is also under active study.
Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Case report; PH3; hyperoxaluria; kidney failure; kidney stone; mitochondrial 4-hydroxy-2-oxoglutarate aldolase (HOGA1); mutation; oxalate; primary hyperoxaluria (PH); urinary tract infections (UTIs)

Mesh:

Substances:

Year:  2021        PMID: 34245816      PMCID: PMC8692335          DOI: 10.1053/j.ajkd.2021.05.016

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   11.072


  20 in total

Review 1.  Primary hyperoxaluria.

Authors:  Pierre Cochat; Gill Rumsby
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

2.  Late diagnosis of primary hyperoxaluria type III.

Authors:  Emmanuel Richard; Jean-Marc Blouin; Jérome Harambat; Brigitte Llanas; Stéphane Bouchet; Cécile Acquaviva; Renaud de la Faille
Journal:  Ann Clin Biochem       Date:  2017-01-10       Impact factor: 2.057

Review 3.  Investigational Therapies for Primary Hyperoxaluria.

Authors:  Anna Kletzmayr; Mattias E Ivarsson; Jean-Christophe Leroux
Journal:  Bioconjug Chem       Date:  2020-06-29       Impact factor: 4.774

Review 4.  An update on primary hyperoxaluria.

Authors:  Bernd Hoppe
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

5.  Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.

Authors:  Sander F Garrelfs; Gill Rumsby; Hessel Peters-Sengers; Florian Erger; Jaap W Groothoff; Bodo B Beck; Michiel J S Oosterveld; Alessandra Pelle; Thomas Neuhaus; Brigitte Adams; Pierre Cochat; Eduardo Salido; Graham W Lipkin; Bernd Hoppe; Sally-Anne Hulton
Journal:  Kidney Int       Date:  2019-09-03       Impact factor: 10.612

Review 6.  The primary hyperoxalurias: an algorithm for diagnosis.

Authors:  Dawn S Milliner
Journal:  Am J Nephrol       Date:  2005-04-22       Impact factor: 3.754

7.  Pathophysiology and Treatment of Enteric Hyperoxaluria.

Authors:  Celeste Witting; Craig B Langman; Dean Assimos; Michelle A Baum; Annamaria Kausz; Dawn Milliner; Greg Tasian; Elaine Worcester; Meaghan Allain; Melissa West; Felix Knauf; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-08       Impact factor: 8.237

8.  Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

Authors:  Sander F Garrelfs; Yaacov Frishberg; Sally A Hulton; Michael J Koren; William D O'Riordan; Pierre Cochat; Georges Deschênes; Hadas Shasha-Lavsky; Jeffrey M Saland; William G Van't Hoff; Daniel G Fuster; Daniella Magen; Shabbir H Moochhala; Gesa Schalk; Eva Simkova; Jaap W Groothoff; David J Sas; Kristin A Meliambro; Jiandong Lu; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; John M Gansner; Tracy L McGregor; John C Lieske
Journal:  N Engl J Med       Date:  2021-04-01       Impact factor: 91.245

9.  Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.

Authors:  Prince Singh; Jason K Viehman; Ramila A Mehta; Andrea G Cogal; Linda Hasadsri; Devin Oglesbee; Julie B Olson; Barbara M Seide; David J Sas; Peter C Harris; John C Lieske; Dawn S Milliner
Journal:  Nephrol Dial Transplant       Date:  2022-04-25       Impact factor: 7.186

10.  Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) AGXT Gene Mutation.

Authors:  Prince Singh; Fouad T Chebib; Andrea G Cogal; Dimitar K Gavrilov; Peter C Harris; John C Lieske
Journal:  Kidney Int Rep       Date:  2020-04-13
View more
  3 in total

Review 1.  New Aspects of Kidney Fibrosis-From Mechanisms of Injury to Modulation of Disease.

Authors:  Marcus J Moeller; Rafael Kramann; Twan Lammers; Bernd Hoppe; Eicke Latz; Isis Ludwig-Portugall; Peter Boor; Jürgen Floege; Christian Kurts; Ralf Weiskirchen; Tammo Ostendorf
Journal:  Front Med (Lausanne)       Date:  2022-01-12

Review 2.  Improving Treatment Options for Primary Hyperoxaluria.

Authors:  Bernd Hoppe; Cristina Martin-Higueras
Journal:  Drugs       Date:  2022-07-02       Impact factor: 11.431

3.  Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I.

Authors:  Pia Recker; Bodo Bernhard Beck; Przemyslaw Sikora; Heike Göbel; Markus Josef Kemper; Angel Nazco; Cristina Martin-Higueras; Bernd Hoppe
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.